Ontada received funding from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc, Rahway, NJ, USA for conducting this study. JH Goldschmidt: employee of The US Oncology Network, consulting or advisory role (Amgen), speakers bureau (G1 Therapeutics). S Annavarapu: employee of Ontada. D Venkatasetty, MPH: employee of Ontada. Y Wang: employee of Ontada. ML Santorelli: employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, and stockholder of Merck & Co., Inc., Rahway, NJ, USA. T Burke: employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, New Jersey, and stockholder of Merck & Co., Inc., Rahway, NJ, USA. NA Pennell: consulting or advisory roles with Lilly, Merck, Genentech, Pfizer, Janssen Oncology, Sanofi/Regeneron, ResistanceBio, Takeda, Novartis, Anheart, Iovance, and Bayer; and research funding (to their institution) from Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, BMS, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, Altor, WindMIL, Anheart, Navire, Summit, and Sanofi. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.